Description
Emlino 25/5, manufactured by ACME Laboratories Ltd., is a combination tablet containing 25 mg of empagliflozin and 5 mg of linagliptin. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The recommended starting dose is one tablet daily, taken in the morning with or without food. The dose may be increased to 25 mg of empagliflozin and 5 mg of linagliptin once daily, depending on individual patient needs. Before initiating treatment, renal function should be assessed, and the medication should not be started if the estimated glomerular filtration rate (eGFR) is below 45 mL/min/1.73 m². Common side effects include urinary tract infections, upper respiratory tract infections, and nasopharyngitis. Serious adverse reactions may include pancreatitis, ketoacidosis, and Fournier’s gangrene. This medication is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also not recommended during the second and third trimesters of pregnancy. Patients should be monitored for signs of volume depletion, urinary tract infections, and other potential adverse effects during treatment
.jpeg)
.png)
.webp)
.jpeg)
.webp)
.png)
.webp)
.jpeg)
.png)
Change Language